LIXTE Biotechnology Holdings to Present at the Spartan Capital Investor Conference 2025, November 3

BOCA RATON, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT, LIXTW), a clinical-stage pharmaceutical company advancing LB-100, a first-in-class inhibitor of protein phosphatase 2A (PP2A), today announced that Geordan Pursglove, its chief executive officer, will present at the Spartan Capital Investor Conference 2025 in New York, on November 3, 2025, at 4 p.m. ET. Management will conduct one-on-one meetings with investors during the conferen ...